The RA-MAP Consortium: a working model for academia-industry collaboration
Research output: Contribution to journal › Review article › peer-review
Colleges, School and Institutes
- King’s College London
- Queen Mary, University of London
- Newcastle University
- Janssen-Cilag Limited
- University of Glasgow
- University of Leeds
- University College London Hospitals NHS Foundation Trust
- UCB Pharma, Monheim
- Elsai, UK.
- Roche Prod
- GRUNENTHAL GMBH
- Protagen AG, UK.
- University of Manchester
- University of Oxford
- University of Cambridge
Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.
|Number of pages||8|
|Journal||Nature Reviews Rheumatology|
|Early online date||7 Dec 2017|
|Publication status||E-pub ahead of print - 7 Dec 2017|
- Arthritis, Rheumatoid, Biomarkers, Biomedical Research, Cooperative Behavior, Genomics, History, 21st Century, Humans, Industry, Phenotype, Research, United Kingdom, Historical Article, Journal Article, Review